Study of Everolimus (RAD001) in Combination With Lenalidomide
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the combination of two anticancer drugs, everolimus
(RAD001) and lenalidomide in patients whose cancer is no longer responding to standard
treatment or patients who are unable to tolerate the standard treatment for their cancer.